Statistiche di base
| CIK | 1305591 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Helix BioPharma Corp.
SEC Filings (Chronological Order)
Questa pagina fornisce un elenco completo e cronologico dei depositi SEC, esclusi i documenti di proprietà che forniamo altrove.
| July 19, 2012 |
HELIX BIOPHARMA CORP. ANNOUNCES FILING OF FORM 15F TO TERMINATE SEC REPORTING OBLIGATIONS EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JULY 19, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com July 19, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES FILING OF FORM 15F TO TERMINATE SEC REPORTING OBLIGATIONS (Aurora, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”), a biopharmaceu |
|
| July 19, 2012 |
- REGISTRATION STATEMENT DATED NOVEMBER 8, 2010 - POST-EFFECTIVE AMENDMENT NO. 1 As filed with the Securities and Exchange Commission on July 18, 2012 Registration No. |
|
| July 19, 2012 |
- CERTIFICATION OF TERMINATION DATED JULY 19, 2012 Filed by e3 Filing, Computershare 1-800-973-3274 - Helix Biopharma Corp. - Form 15F UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15F CERTIFICATION OF A FOREIGN PRIVATE ISSUER’S TERMINATION OF REGISTRATION OF A CLASS OF SECURITIES UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ITS TERMINATION OF THE DUTY TO FILE REPORTS UNDER SECTION 13(a) OR SECTION 1 |
|
| July 9, 2012 |
Filed by e3 Filing, Computershare 1-800-973-3274 - Helix BioPharma Corp - Form 25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 5, 2012 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Helix BioPharma Corp. #3 - 305 Industrial Parkway South Aurora, Ontario L4G 6X 2. Date of Material Change June 25, 2012. 3. News Release On June 25, 2012, a news release was issued through the facilities of Marketwire and filed on SEDAR. A copy of the news release is attached as Schedule A. 4. Summary of Material Chan |
|
| July 5, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JULY, 2012 6-K 1 helix6kmcr120704.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JULY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2012 Commission File Number: 000-53508 HELIX BIOPHARMA CORP. (Exact name of registrant as specified |
|
| June 27, 2012 |
Helix BioPharma Corp. Actions Taken in Response to FK Partner Sp. z o.o Due Diligence Report EX-99.2 3 exhibit99-2.htm ACTIONS TAKEN IN RESPONSE TO FK PARTNER DUE DILIGENCE REPORT Exhibit 99.2 Helix BioPharma Corp. Actions Taken in Response to FK Partner Sp. z o.o Due Diligence Report The following lists key observations taken by Management at Helix BioPharma Corp. from the FK Partner Due Diligence report and actions underway or under consideration. Observation: Audit costs relatively hig |
|
| June 27, 2012 |
HELIX BIOPHARMA CORP. ANNOUNCES SELECTION OF CEO; PLANS TO VOLUNTARILY DELIST FROM NYSE MKT EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JUNE 25, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com June 25, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES SELECTION OF CEO; PLANS TO VOLUNTARILY DELIST FROM NYSE MKT (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE MKT, FSE: “HBP”), a |
|
| June 27, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JUNE, 2012 6-K 1 helix6knr120625.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JUNE, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2012 Commission File Number: 000-53508 HELIX BIOPHARMA CORP. (Exact name of registrant as specified |
|
| June 27, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JUNE, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2012 Commission File Number: 000-53508 HELIX BIOPHARMA CORP. (Exact name of registrant as specified in its charter) 305 INDUSTRIAL PARKWAY SOUTH, #3, AURORA, ONTARIO, CANADA, L4G 6X7 (Add |
|
| June 27, 2012 |
SUMMARY DUE DILIGENCE REPORT FOR PUBLIC DISTRIBUTION Date: 21.05.2012 © 2012 FK Partner Sp. z o.o. EX-99.1 2 exhibit99-1.htm FK PARTNER SP. Z O.O DUE DILIGENCE REPORT Exhibit 99.1 for SUMMARY DUE DILIGENCE REPORT FOR PUBLIC DISTRIBUTION Date: 21.05.2012 © 2012 FK Partner Sp. z o.o. 1 Summary Due Diligence Report for Public Distribution A Due Diligence Report was delivered by FK Partner Sp. z o.o. to the Board of Directors of Helix BioPharma Corp. This Summary Due Diligence Report for Public Dis |
|
| June 15, 2012 |
HELIX BIOPHARMA CORP. ANNOUNCES Q3 2012 RESULTS AND ACTIONS TAKEN BY ITS NEW BOARD EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JUNE 14, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com June 14, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES Q3 2012 RESULTS AND ACTIONS TAKEN BY ITS NEW BOARD (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE MKT, FSE: “HBP”), a biopharma |
|
| June 15, 2012 |
Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.5 6 exhibit99-5.htm FORM 52-109F2 - CFO CERTIFICATION Exhibit 99.5 Form 52-109F2 Certification of Interim Filings Full Certificate I, Photios (Frank) Michalargias, Chief Financial Officer of Helix BioPharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Helix BioPharma Corp. (the “issuer”) for the in |
|
| June 15, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JUNE, 2012 6-K 1 helix6kq3120430.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JUNE, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into E |
|
| June 15, 2012 |
EX-99.3 4 exhibit99-3.htm MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE PERIOD ENDED APRIL 30, 2012 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE THIRD QUARTER OF FISCAL 2012 (Three and Nine Month Periods Ended April 30, 2012) The following information should be read in conjunction with Helix BioPharma Corp.’s (the “Company” or “Helix”) condensed unaudited interim consolidated financial |
|
| June 15, 2012 |
Form 52-109F2 Certification of Interim Filings Full Certificate EX-99.4 5 exhibit99-4.htm FORM 52-109F2 - CEO CERTIFICATION Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, William White, interim Chief Executive Officer of Helix BioPharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Helix BioPharma Corp. (the “issuer”) for the interim p |
|
| June 15, 2012 |
EX-99.2 3 exhibit99-2.htm INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED APRIL 30, 2012 Exhibit 99.2 Condensed unaudited interim consolidated financial statements For the three and nine month periods ended April 30, 2012 and 2011 In accordance with National Instruments 51-102 released by the Canadian Securities Administrators, the Company discloses that its auditors have not reviewed the unaudi |
|
| May 22, 2012 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED MAY 18, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Telephone: (905) 841-2300 Facscimile: (905) 841-2244 Website: www.helixbiopharma.com May 18, 2012 News Release HELIX BIOPHARMA CORP. RECEIVES REGULATORY APPROVAL TO CONDUCT A EUROPEAN PHASE III CLINICAL TRIAL OF TOPICAL INTERFERON ALPHA-2B IN PATIENTS WITH LOW-GR |
|
| May 22, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 6-K 1 helix6knr120518.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into Eng |
|
| May 15, 2012 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED MAY 14, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Telephone: (905) 841-2300 Facscimile: (905) 841-2244 Website: www.helixbiopharma.com May 14, 2012 News Release HELIX BIOPHARMA CORP. COMMENCES POLISH PHASE I/II CLINICAL STUDY OF ITS LUNG CANCER DRUG CANDIDATE L-DOS47 AURORA, Ontario, May 14, 2012 – Helix BioPhar |
|
| May 15, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 6-K 1 helix6knr1205014.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into En |
|
| May 8, 2012 |
HELIX BIOPHARMA CORP. UPDATES SHAREHOLDERS ON COURT APPROVAL OF SETTLEMENT Exhibit 99.1 HELIX BIOPHARMA CORP. UPDATES SHAREHOLDERS ON COURT APPROVAL OF SETTLEMENT (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”) announced today that it has obtained an Order of the Ontario Superior Court of Justice approving the settlement that Helix entered into with the Concerned Shareholders and others on March 14, 2012, and dismissing the related court proceeding |
|
| May 8, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 6-K 1 helix6knr120507.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into Eng |
|
| May 4, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 6-K 1 helix6knr120503.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into Eng |
|
| May 4, 2012 |
HELIX BIOPHARMA CORP. UPDATES SHAREHOLDERS ON ELECTION OF DIRECTORS EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED MAY 3, 2012 Exhibit 99.1 HELIX BIOPHARMA CORP. UPDATES SHAREHOLDERS ON ELECTION OF DIRECTORS (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”) announced today that, in compliance with applicable corporate law, it is seeking an Order of the Ontario Superior Court of Justice approving the settlement that Helix entered into with the |
|
| April 9, 2012 |
HELIX BIOPHARMA CORP. RECONSTITUTED BOARD OF DIRECTORS PROVIDES UPDATE TO SHAREHOLDERS EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED APRIL 5, 2012 Exhibit 99.1 HELIX BIOPHARMA CORP. RECONSTITUTED BOARD OF DIRECTORS PROVIDES UPDATE TO SHAREHOLDERS (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), announced today that its recently reconstituted Board of Directors has met and commenced a detailed review with independent advisors of the Company’s operations and cu |
|
| April 9, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF APRIL, 2012 6-K 1 helixbiopharma6knr120405.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF APRIL, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s |
|
| March 27, 2012 |
HBPCF / Helix Biopharma Corp. / Hajduk Wojciech - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HELIX BIOPHARMA CORP. (Name of issuer) Common Shares, no par value (Title of class of securities) 422910109 (CUSIP number) March 14, 2012 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| March 27, 2012 |
HBPCF / Helix Biopharma Corp. / Flejsierowicz Izabela - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HELIX BIOPHARMA CORP. (Name of issuer) Common Shares, no par value (Title of class of securities) 422910109 (CUSIP number) March 14, 2012 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursua |
|
| March 26, 2012 |
ONTARIO SUPERIOR COURT OF JUSTICE (COMMERCIAL LIST) EX-99.1 2 exhibit99-1.htm MATERIAL CONTRACT, DATED MARCH 14, 2012 Exhibit 99.1 Court File No. CV-11-9504-00CL ONTARIO SUPERIOR COURT OF JUSTICE (COMMERCIAL LIST) BETWEEN: JACK M. KAY AND W. THOMAS HODGSON, IN THEIR CAPACITY AS THE SPECIAL COMMITTEE OF THE BOARD OF DIRECTORS OF HELIX BIOPHARMA CORP. Applicants - and - ANDREAS KANDZIORA, VERONIKA KANDZIORA, ACM ALPHA CONSULTING MANAGEMENT EST., ACM |
|
| March 26, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into English) 305 INDUSTRIAL PARKWAY SOUTH, #3, AURORA, ONTARIO, CANADA L4G 6X7 (Address of |
|
| March 26, 2012 |
Form 51-102F3 Material Change Report EX-99 2 exhibit99-1.htm MATERIAL CHANGE REPORT, DATED MARCH 23, 2012 Exhibit 99.1 Form 51-102F3 Material Change Report 1. Name and Address of Company Helix BioPharma Corp. #3 - 305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 2. Date of Material Changes March 14 and March 16, 2012. 3. News Releases News releases with respect to these material changes were disseminated on March 14, 201 |
|
| March 26, 2012 |
Exhibit 99.2 Exhibit 99.2 SCHEDULE A News Release dated March 14, 2012 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com March 14, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES AGREED CHANGES TO THE BOARD OF DIRECTORS AND SETTLEMENT WITH CONCERNED SHAREHOLDERS AURORA, ON-(Marketwire – March 14, 2012) - Helix Bi |
|
| March 26, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 6-K 1 helixbiopharma6knr120323.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s |
|
| March 26, 2012 |
HELIX BIOPHARMA CORP. ANNOUNCES Q2 2012 RESULTS CONFIRMS RECONSTITUTED BOARD OF DIRECTORS Exhibit 99.3 SCHEDULE B News Release dated March 16, 2012 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com March 16, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES Q2 2012 RESULTS CONFIRMS RECONSTITUTED BOARD OF DIRECTORS (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutica |
|
| March 23, 2012 |
HBPCF / Helix Biopharma Corp. / Cacek Sylvester - SCHEDULE 13G Passive Investment SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HELIX BIOPHARMA CORP. (Name of issuer) Common Shares, no par value (Title of class of securities) 422910109 (CUSIP number) March 14, 2012 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| March 21, 2012 |
HBPCF / Helix Biopharma Corp. / Lobacz Zbigniew - SCHEDULE 13G Passive Investment SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* HELIX BIOPHARMA CORP. (Name of issuer) Common Shares, no par value (Title of class of securities) 422910109 (CUSIP number) March 14, 2012 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule |
|
| March 20, 2012 |
HBPCF / Helix Biopharma Corp. / ACM Alpha Consulting Management AG - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Helix BioPharma Corp. (Name of issuer) Common Shares, no par value (Title of class of securities) 422910109 (CUSIP number) Veronika Kandziora ACM Alpha Consulting Management AG Sihleggstrasse 23 CH – 8832 Wollerau, Switzerland +41 76 208 2084 (N |
|
| March 19, 2012 |
Exhibit 99.2 Condensed unaudited interim consolidated financial statements For the three and six month periods ended January 31, 2012 and 2011 HELIX BIOPHARMA CORP. Condensed Consolidated Statement of Financial Position In thousands of Canadian dollars Unaudited As at: January 31, 2012 July 31, 2011 (note 14) ASSETS Current assets Cash and cash equivalents $ 9,280 $ 19,044 Cash held in escrow (not |
|
| March 19, 2012 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Donald H. Segal, Chief Executive Officer of Helix BioPharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Helix BioPharma Corp. (the “issuer”) for the interim period ended January 31, 2012. 2. No misrepresentation |
|
| March 19, 2012 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.5 Exhibit 99.5 Form 52-109F2 Certification of Interim Filings Full Certificate I, Photios (Frank) Michalargias, Chief Financial Officer of Helix BioPharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Helix BioPharma Corp. (the “issuer”) for the interim period ended January 31, 2012. 2. No misr |
|
| March 19, 2012 |
MANAGEMENT’S DISCUSSION AND ANALYSIS Exhibit 99.3 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER OF FISCAL 2012 (Three and Six Month Periods Ended January 31, 2012) The following information should be read in conjunction with Helix BioPharma Corp.’s (the “Company” or “Helix”) condensed unaudited interim consolidated financial statements and note disclosure for the three and six month periods ended January 31 |
|
| March 19, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 6-K 1 helix6kq2120131.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into |
|
| March 19, 2012 |
HELIX BIOPHARMA CORP. ANNOUNCES Q2 2012 RESULTS CONFIRMS RECONSTITUTED BOARD OF DIRECTORS Exhibit 99.1 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com March 16, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES Q2 2012 RESULTS CONFIRMS RECONSTITUTED BOARD OF DIRECTORS (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing drug candid |
|
| March 15, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2011 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into English) 305 INDUSTRIAL PARKWAY SOUTH, #3, AURORA, ONTARIO, CANADA L4G 6X7 (Address |
|
| March 15, 2012 |
The Special Committee of Helix BioPharma Corp. Provides Update to Shareholders EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED MARCH 14, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com December 6, 2011 NEWS RELEASE The Special Committee of Helix BioPharma Corp. Provides Update to Shareholders AURORA, Ontario, December 6, 2011 – The Special Committee of Helix BioPharma Corp. |
|
| March 2, 2012 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED MARCH 1, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com March 01, 2012 NEWS RELEASE Helix BioPharma Corp. announces L-DOS47 Scientific Presentation to be made at the Second Annual IBC Conference on Analytical Technologies Biotherapeutic Development |
|
| March 2, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MARCH, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into English) 305 INDUSTRIAL PARKWAY SOUTH, #3, AURORA, ONTARIO, CANADA L4G 6X7 (Address of |
|
| February 2, 2012 |
Exhibit A Exhibit A The Concerned Shareholders of Helix BioPharma Corp. to Vigorously Challenge the Chairman’s Decisions with Respect to the January 30, 2012 Annual Meeting TORONTO, January 30, 2012 (Marketwire) — The Concerned Shareholders are outraged that the rights of a majority of Helix shareholders have been denied by the decisions made by Mr. Jack Kay, the Chairman of Helix, at the January |
|
| February 2, 2012 |
Schedule 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Helix BioPharma Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 422910109 (CUSIP Number) Veronika Kandziora ACM Alpha Consulting Management AG Sihleggstrasse 23 CH – 8832 Wollerau, Switzerland +41 76 208 2 |
|
| January 31, 2012 |
HELIX BIOPHARMA CORP. UPDATES SHAREHOLDERS ON RESULTS FROM ANNUAL GENERAL MEETING EX-99.2 3 exhibit99-2.htm PRESS RELEASE, DATED JANUARY 30, 2012 Exhibit 99.2 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 30, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. UPDATES SHAREHOLDERS ON RESULTS FROM ANNUAL GENERAL MEETING AURORA, ON-(Marketwire - Jan 30, 2012) - Helix BioPharma Corp. (TSX: HBP) (NY |
|
| January 31, 2012 |
HELIX BIOPHARMA CORP. REPORT OF VOTING RESULTS EX-99.1 2 exhibit99-1.htm REPORT ON ANNUAL GENERAL MEETING, DATED JANUARY 30, 2012 Exhibit 99.1 HELIX BIOPHARMA CORP. REPORT OF VOTING RESULTS This report describes the matters voted on and the outcome of the votes at the Annual General and Meeting of Helix BioPharma Corp. held January 30, 2012 (the “Meeting”). Appointment of Auditor KPMG LLP, Chartered Accountants, was appointed as auditor of the |
|
| January 31, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 6-K 1 helix6k120131.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name in |
|
| January 26, 2012 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JANUARY 25, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 25, 2012 NEWS RELEASE SPECIAL COMMITTEE OF HELIX BIOPHARMA CORP. PROVIDES UPDATE TO SHAREHOLDERS INTERIM REPORT OF ERNST & YOUNG LLP RECEIVED AURORA, Ontario, January 25, 2012 – The |
|
| January 26, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 6-K 1 helixbiopharma6knr120125.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registran |
|
| January 24, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 6-K 1 helix6k2nr120123.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name |
|
| January 24, 2012 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JANUARY 23, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 23, 2012 NEWS RELEASE Helix BioPharma Corp. Announces that Institutional Shareholder Services Recommends Shareholders Vote for Management’s Director Nominees AURORA, Ontario, Januar |
|
| January 23, 2012 |
EX-99.1 2 exhibit99-1.htm LETTER TO SHAREHOLDERS IN CONNECTION WITH JANUARY 2012 ANNUAL GENERAL MEETING Exhibit 99.1 LETTER TO SHAREHOLDERS IN CONNECTION WITH THE JANUARY 2012 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT Sheraton Parkway Toronto North 600 Highway 7 East Richmond Hill, ON Canada Monday, January 30, 2012 10:00 a.m. (Toronto time) THE MANAGEMENT PROXY CIRCULAR DATED DECEMBER |
|
| January 23, 2012 |
EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JANUARY 23, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 23, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. RESPONDS TO DISSIDENT PROXY CIRCULAR IN CONNECTION WITH THE JANUARY 30, 2012 SHAREHOLDER MEETING AURORA, Ontario, January 23, 2012 – Heli |
|
| January 23, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 6-K 1 helix6k120123.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name in |
|
| January 23, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into English) 305 INDUSTRIAL PARKWAY SOUTH, #3, AURORA, ONTARIO, CANADA L4G 6X7 (Address o |
|
| January 17, 2012 |
Exhibit D Exhibit D Helix BioPharma Corp. The Concerned Shareholders of Helix BioPharma Corp. File Proxy Circular in Connection With the January 30, 2012 Annual General Meeting of Shareholders TORONTO, January 13 (Marketwire) — A group of concerned shareholders (“Concerned Shareholders”) of Helix BioPharma Corp. (“Helix”), led by Mr. Zbigniew Lobacz, a significant shareholder, announced today the |
|
| January 17, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 6-K 1 helix6kq111031.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name i |
|
| January 17, 2012 |
HELIX BIOPHARMA CORP. ANNOUNCES Q1 2012 RESULTS EX-99.1 2 exhibit99-1.htm PRESS RELEASE, DATED JANUARY 13, 2012 Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 13, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. ANNOUNCES Q1 2012 RESULTS (Aurora, Ontario) – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: “HBP”), a biopharmaceutical company developing |
|
| January 17, 2012 |
MANAGEMENT’S DISCUSSION AND ANALYSIS EX-99.3 4 exhibit99-3.htm MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE PERIOD ENDED OCTOBER 31, 2011 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER OF FISCAL 2012 (Three Month Period Ended October 31, 2011) The following information should be read in conjunction with Helix BioPharma Corp.’s (the “Company” or “Helix”) condensed unaudited interim consolidated financial state |
|
| January 17, 2012 |
Amendment No. 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Helix BioPharma Corp. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 422910109 (CUSIP Number) Veronika Kandziora ACM Alpha Consulting Management AG Sihleggstrasse 23 CH – 8832 Wollerau, Switzerland +41 76 208 |
|
| January 17, 2012 |
JOINDER AGREEMENT to JOINT FILING AGREEMENT Exhibit C Exhibit C JOINDER AGREEMENT to JOINT FILING AGREEMENT The undersigned hereby agrees to join as a party to that certain joint filing Agreement, dated November 10, 2011, among ACM Alpha Consulting Management AG,Veronika Kandziora, ACM Alpha Consulting Management Est. |
|
| January 17, 2012 |
Exhibit 99.2 Exhibit 99.2 Condensed Unaudited Interim Consolidated Financial Statements For the three months ended October 31, 2011 and 2010 HELIX BIOPHARMA CORP. Condensed Consolidated Statement of Financial Position In thousands of Canadian dollars Unaudited As at: October 31, 2011 July 31, 2011 August 1, 2010 (note 14) (note 14) ASSETS Current assets Cash and cash equivalents $ 17,654 $ 19,044 |
|
| January 17, 2012 |
Exhibit A Exhibit A DISSIDENT PROXY CIRCULAR TO BE USED IN CONNECTION WITH THE MEETING OF HOLDERS OF COMMON SHARES OF HELIX BIOPHARMA CORP. |
|
| January 17, 2012 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.4 Exhibit 99.4 Form 52-109F2 Certification of Interim Filings Full Certificate I, Donald H. Segal, Chief Executive Officer of Helix BioPharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Helix BioPharma Corp. (the “issuer”) for the interim period ended October 31, 2011. 2. No misrepresentation |
|
| January 17, 2012 |
Form 52-109F2 Certification of Interim Filings Full Certificate Exhibit 99.5 Exhibit 99.5 Form 52-109F2 Certification of Interim Filings Full Certificate I, Photios (Frank) Michalargias, Chief Financial Officer of Helix BioPharma Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Helix BioPharma Corp. (the “issuer”) for the interim period ended October 31, 2011. 2. No misr |
|
| January 9, 2012 |
Proxies submitted must be received by 10:00 am, Eastern Time, on January 26, 2012. EX-99.4 5 exhibit99-4.htm FORM OF PROXY Exhibit 99.4 BLUE 9th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Form of Proxy - Annual General Meeting to be held on January 30, 2012 This Form of Proxy is solicited by and on behalf of Management. Notes to proxy 1. Every holder has the right to appoint some other person or company of the |
|
| January 9, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY 2012 6-K 1 helix6kagm111227.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name |
|
| January 9, 2012 |
Please return completed form to: Exhibit 99.6 Exhibit 99.6 Please return completed form to: Computershare 9th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 ¨ Interim Financial Statements Mark this box if you would like to receive Interim Financial Statements by mail. ¨ Annual Financial Statements Mark this box if you would like to receive the Annual Financial Statements by mail. Financial Statements Request Form Rather th |
|
| January 9, 2012 |
Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 6, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. PROPOSES NEW BOARD SLATE FOR JANUARY 30, 2012 ANNUAL GENERAL MEETING Also Announces AGM Location, Proxy Material Mailing and Corporate Growth Strategy Shareholders are Urged to Act Now and Vote their Sh |
|
| January 9, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 Filed by e3 Filing, Computershare 1-800-973-3274 - Helix BioPharma Corp. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into E |
|
| January 9, 2012 |
VIFs submitted must be received by 10:00 am, Eastern Time, on January 26, 2012. Exhibit 99.5 Exhibit 99.5 BLUE 9th Floor, 100 University Avenue Toronto, Ontario M5J 2Y1 www.computershare.com Security Class Holder Account Number Intermediary Voting Instruction Form ("VIF") - Annual General Meeting to be held on January 30, 2012 NON-REGISTERED (BENEFICIAL) SHAREHOLDERS 1. We are sending to you the enclosed proxy-related materials that relate to a meeting of the holders of the s |
|
| January 9, 2012 |
Current Report of Foreign Issuer - REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2012 Filed by e3 Filing, Computershare 1-800-973-3274 - Helix BioPharma Corp. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2012 Commission File Number 000-53508 HELIX BIOPHARMA CORP. (Translation of registrant’s name into E |
|
| January 9, 2012 |
begin 644 exhibit99-3.pdf M)5!$1BTQ+C4-)>+CS],-"C(P-R`P(&]B:@T\/"],:6YE87)I>F5D(#$O3"`S M,S`Q-C$O3R`R,#DO12`U,3$U,"].(#0T+U0@,S(Y-30P+T@@6R`T.38@-3%LR,#<@ M,S1=+TEN9F\@,C`V(#`@4B],96YG=&@@.#F4@,C0Q+U1Y<&4O6%)E9B]76S$@,B`Q73X^4^`@08`$;P"S<-"F5N M9'-T65Y9,WUFY\R9ECA2= MF&,MSHH1%SI2M$)`K*"E&Q<*G`@S49+D@DEH2PGRM'K-`+.$1)R3G10GK,EP M,1+50K"Z'X#U+C-1T6B#L;1"%$%&18"(D)6]'&[email protected]+"8EJ"=Q` M,G["RI!X |
|
| January 9, 2012 |
Exhibit 99.2 HELIX BIOPHARMA CORP. NOTICE AND MANAGEMENT PROXY CIRCULAR FOR THE JANUARY 2012 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT Sheraton Parkway Toronto North 600 Highway 7 East Richmond Hill, ON Canada Monday, January 30, 2012 10:00 a.m. (Toronto time) THIS MANAGEMENT PROXY CIRCULAR SOLICITS BLUE PROXIES There are a number of important matters that each shareholder should carefu |
|
| January 9, 2012 |
Exhibit 99.1 3-305 Industrial Parkway South Aurora, Ontario, Canada, L4G 6X7 Phone: (905) 841-2300 Fax: (905) 841-2244 Web: www.helixbiopharma.com January 9, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. APPOINTS JACK KAY AS CHAIRMAN OF THE BOARD AND PROFESSOR KAZIMIERZ ROSZKOWSKI- ŚLIŹ AS EUROPEAN MEDICAL DIRECTOR AURORA, Ontario, January 9, 2012 – Helix BioPharma Corp. (TSX, NYSE Amex, FSE: HBP) (the |
|
| January 9, 2012 |
EX-99.1 2 exhibit99-1.htm NOTICE AND PROXY CIRCULAR DATED DECEMBER 27, 2011 Exhibit 99.1 HELIX BIOPHARMA CORP. NOTICE AND MANAGEMENT PROXY CIRCULAR FOR THE JANUARY 2012 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD AT Sheraton Parkway Toronto North 600 Highway 7 East Richmond Hill, ON Canada Monday, January 30, 2012 10:00 a.m. (Toronto time) THIS MANAGEMENT PROXY CIRCULAR SOLICITS BLUE PROXIES |
